Anthem (NASDAQ:ANTX) Stock: Insider Joshua Eizen Sells 2,826 Shares

Anthem, Inc. (NASDAQ:ANTX) insider Joshua Eizen sold 2,826 shares of the business’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $4.22, for a total value of $11,925.72. Following the transaction, the insider owned 207,546 shares in the company, valued at approximately $875,844.12. This trade represents a 1.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anthem Price Performance

Shares of NASDAQ:ANTX opened at $4.00 on Friday. The business’s 50-day moving average is $4.74 and its 200 day moving average is $4.11. Anthem, Inc. has a 1 year low of $1.00 and a 1 year high of $7.19. The firm has a market capitalization of $150.96 million, a P/E ratio of -3.74 and a beta of -0.93.

Anthem (NASDAQ:ANTX) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter.

Institutional Trading of Anthem

Large investors have recently made changes to their positions in the company. Vivo Capital LLC purchased a new stake in shares of Anthem during the first quarter worth $10,785,000. Commodore Capital LP purchased a new position in shares of Anthem in the first quarter worth about $7,981,000. Spruce Street Capital LP acquired a new position in Anthem during the first quarter worth about $5,576,000. Ally Bridge Group NY LLC acquired a new position in Anthem during the first quarter worth about $1,800,000. Finally, Russell Investments Group Ltd. boosted its position in Anthem by 10,422.0% during the third quarter. Russell Investments Group Ltd. now owns 222,225 shares of the company’s stock worth $1,182,000 after acquiring an additional 220,113 shares during the last quarter. 90.47% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on ANTX. Guggenheim began coverage on shares of Anthem in a research note on Monday, July 20th. They set a “buy” rating and a $9.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anthem in a research note on Friday, October 2nd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $9.00.

About Anthem

An2 Therapeutics, Inc is a clinical-stage biopharmaceutical company that traded on the Nasdaq under the symbol ANTX. The company focused on developing novel treatments for serious infectious diseases, with its lead candidate, epetraborole, designed as an oral therapy for pulmonary disease caused by nontuberculous mycobacteria (NTM).

Epetraborole was evaluated in clinical studies involving patients with refractory Mycobacterium avium complex pulmonary disease, a difficult-to-treat infection that primarily affects the lungs.